Rosetta Genomics (ROSGQ) Price & Analysis

Rosetta Genomics Ltd. is a global entity specializing in genomic diagnostics. The company leverages its proprietary microRNA technologies to offer a range of diagnostic assays, including RosettaGX Cancer Origin, which helps pinpoint the primary source of metastatic cancer; mi-KIDNEY, designed for classifying kidney tumors from pathological specimens; RosettaGX Reveal, used to interpret indeterminate thyroid fine-needle aspirate results; and various mi-LUNG diagnostic tests. In addition to its microRNA-based portfolio, Rosetta Genomics provides UroVysion, a urine-based Fluorescence In Situ Hybridization (FISH) assay. This assay serves as an adjunct to, rather than a substitute for, conventional diagnostic methods, aiding in the initial detection of bladder carcinoma in patients with hematuria and in the ongoing surveillance for tumor recurrence in those previously diagnosed with bladder cancer. The company also offers ERG/PTEN, which are FISH-based tests providing prognostic information for prostate cancer. Furthermore, Rosetta Genomics supplies ALK/ROS1, a set of FISH-based predictive tests specifically intended for individuals with late-stage lung cancer, along with PCR gene mutation analysis for patients with bladder, lung, colon, and melanoma cancers. Its diagnostic solutions are utilized by a diverse group of medical professionals, including oncologists, urologists, endocrinologists, and cytopathologists, empowering them to deliver improved patient care. The company holds a licensing agreement with Max Planck Innovation GmbH, securing rights to its patented microRNA technologies for both diagnostic applications and research initiatives. Moreover, Rosetta Genomics has entered into a collaborative partnership with Meir Medical Center to develop a microRNA classifier, focusing on non-small cell lung cancer patients being considered for immuno-oncology therapies. Established in 2000, Rosetta Genomics Ltd. maintains its headquarters in Rehovot, Israel.